Cabaletta Bio/$CABA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cabaletta Bio
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Ticker
$CABA
Sector
Primary listing
Employees
155
Headquarters
Website
Cabaletta Bio Metrics
BasicAdvanced
$335M
-
-$2.10
3.29
-
Price and volume
Market cap
$335M
Beta
3.29
52-week high
$3.78
52-week low
$0.99
Average daily volume
2.3M
Financial strength
Current ratio
2.769
Quick ratio
2.664
Long term debt to equity
2.569
Total debt to equity
24.184
Interest coverage (TTM)
-85.95%
Profitability
EBITDA (TTM)
-170.595
Management effectiveness
Return on assets (TTM)
-61.49%
Return on equity (TTM)
-126.98%
Valuation
Price to book
2.7
Price to tangible book (TTM)
2.7
Price to free cash flow (TTM)
-1.818
Free cash flow yield (TTM)
-55.01%
Free cash flow per share (TTM)
-1.656
Growth
Earnings per share change (TTM)
-10.22%
3-year earnings per share growth (CAGR)
5.18%
What the Analysts think about Cabaletta Bio
Analyst ratings (Buy, Hold, Sell) for Cabaletta Bio stock.
Cabaletta Bio Financial Performance
Revenues and expenses
Cabaletta Bio Earnings Performance
Company profitability
Cabaletta Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cabaletta Bio stock?
Cabaletta Bio (CABA) has a market cap of $335M as of April 08, 2026.
What is the P/E ratio for Cabaletta Bio stock?
The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of April 08, 2026.
Does Cabaletta Bio stock pay dividends?
No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of April 08, 2026.
When is the next Cabaletta Bio dividend payment date?
Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cabaletta Bio?
Cabaletta Bio (CABA) has a beta rating of 3.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.